Psychopharmacology of Fear-Potentiated Startle in Humans

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00044096
First received: August 16, 2002
Last updated: September 18, 2013
Last verified: September 2013
  Purpose

The purpose of this study is to understand the effects of the drug alprazolam (Xanax ) on anxiety.

To understand the effect of anxiety-relieving drugs on fear and anxiety, researchers often have participants anticipate unpleasant stimuli. Anticipating unpleasant stimuli increases or potentiates a simple reflex called the startle reflex. The so-called fear-potentiated startle reflex (FPS) effect may be blocked or reduced by anxiety-relieving drugs. Evidence suggests that the FPS can be mediated by two mechanisms that regulate the phasic- and sustained enhancement of startle. This study will elicit phasic and sustained FPS in participants by having them anticipate moderately painful stimuli that are administered predictably and unpredictably. The main goal of this study is to assess the affect of alprazolam on the phasic and sustained enhancement of startle.

This study comprises two pilot experiments and a main study. Participants in the study will be screened with a psychiatric history, physical examination, electrocardiogram (EKG), and blood and urine tests. Participants will four testing sessions separated by 5 to 10 days. At each session, participants will be given one of two doses of alprazolam, diphenhydramine, or placebo (an inactive pill). Questionnaires and other tests will be performed.


Condition
Healthy

Study Type: Observational
Official Title: Psychopharmacology of Fear-Potentiated Startle in Humans

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Enrollment: 225
Study Start Date: August 2002
Estimated Study Completion Date: September 2013
Detailed Description:

Objective:

Recent breakthroughs in biomedical research have not improved the ability to identify successful pharmacological treatments derived from novel candidate compounds. This is partly due to the inability of the existing scientific approach to translate candidate anxiolytics identified through the drug discovery process into efficient psychopharmacological treatment of patients. A new drug development approach urgently needs to be implemented to improve predictability and efficiency in translating the basic science explosion into validated drug targets. A key approach to improve the selection of candidate anxiolytics for clinical trials is to fill the gap between animal models and clinical studies in patients by implementing tests in healthy humans with a predictive validity of subsequent clinical efficacy. As a step towards this goal, we developed integrative experimental models of fear and anxiety in non-clinical subjects. We now use these models to identify the anxiolytic and anxiogenic properties of various compounds. The current specific objectives are to 1) further test the psychopharmacological validity of the model using recognized anxiolytics (the SSRI citalopram), 2) test the properties of compounds that are hypothesized to be anxiolytic or anxiogenic (e.g., oxytocin, arginine vasopressin, hydrocortisone) and 3) examine the time course of the anxiolytic effect of the benzodiazepine alprazolam on FPS.

Study population:

Medically and psychiatrically healthy males and females ages 18 to 45.

Design:

The study examines fear and anxiety elicited by unpleasant electric shock delivered predictably and unpredictably, respectively. The following drugs will be tested:

1) Citalopram, 2) oxytocin and arginine vasopressin, 3) hydrocortisone, 4) alprazolam.

Outcome measures:

The primary outcome measure is the startle reflex. Secondary measures include the skin conductance response, the heart rate, and subjective measures of anxiety.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Subjects will be healthy volunteers between 18-45 years old and free of current psychopathology and organic central nervous system disorders.

EXCLUSION CRITERIA:

  • Any significant medical or neurological problems (e.g. cardiovascular illness, respiratory illness, neurologic illness, seizure, etc.)
  • Adverse reactions to cortisol (cortisol study only)
  • Adverse reactions to benzodiazepines or antihistamines (alprazolam study only)
  • History of angioedema
  • Osteoporosis (Hydrocortisone study only)
  • High or low blood pressure
  • History of fainting
  • First degree relative with history of mania, schizophrenia, or other psychoses
  • A history of mania, schizophrenia, or other psychoses
  • Current migraine
  • Use of herbal medicines or dietary supplements with psychoactive properties (citalopram study only)
  • Any current psychiatric disorders
  • Past alcohol/drug dependence and alcohol/drug abuse in past one year
  • Current use of psychotropic medication
  • Impaired hearing
  • Pregnancy
  • Breast-feeding or currently taking contraceptive hormones (oxytocin/vasopressin study only)
  • Positive results of beta-human chorionic gonadotropin testing (females only)
  • Neurological syndrome of the wrist (e.g., carpal tunnel syndrome)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00044096

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Investigators
Principal Investigator: Christian Grillon, Ph.D. National Institute of Mental Health (NIMH)
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00044096     History of Changes
Other Study ID Numbers: 020263, 02-M-0263
Study First Received: August 16, 2002
Last Updated: September 18, 2013
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
SSRI
Anxiety
Stress
Citalopram
Benadryl
Diphenhydramine
Startle
Fear-Potentiated Startle
Fear
Normal Volunteers
Healthy Volunteers
HV

ClinicalTrials.gov processed this record on July 29, 2014